Pipeline

What’s Next: A Growing Body of Evidence to Support Our Platform

Inhalon’s muco-trapping platform has already been proven effective in over a half dozen pathogens to date, with extensive in vitro and in vivo proof-of-concept demonstrations:

 

  • In treating RSV, Inhalon's antibodies produced a ≥ 4-log reduction in viral load in an RSV neonatal lamb model—the “gold-standard” large-animal model, since lamb lung physiology closely matches that of a human infant.

 

  • Our muco-trapping antibodies have also demonstrated activity in mouse and cotton rats infected with RSV.

 

  • The broad applicability of our muco-trapping platform was illustrated by showing the same approach could trap particles similar to the Ebola virus in human airway mucus and facilitate their rapid elimination from mouse lung airways.

 

  • We are currently undertaking preclinical development for our lead anti-RSV antibody, IN-002.

 

Clinical Trial Overview​

Inhalon Biopharma has been awarded a contract by the U.S. Army Medical Research & Development Command to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients, with initial results expected in 2022.